YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Investors in Brookdale Senior Living Inc (Symbol: BKD) saw new options begin trading today, for the November 21st expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the BKD options chain for the new Novembe…
In trading on Monday, shares of Sun Life Financial Inc (Symbol: SLF) crossed above their 200 day moving average of $59.65, changing hands as high as $59.87 per share. Sun Life Financial Inc shares are currently trading up about 0.8% on the…
SOUTH SAN FRANCISCO, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: “CALA”). Calithera Biosciences, Inc. (the “Company”) announced that it was unable to achieve a quorum of stockholders at its special meeting o…
Calithera Biosciences, Inc. Special Meeting to be Held on or about June 29, 2023 with a Record Date of May 25, 2023 SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: CALA) (the “Company”) annou…
SOUTH SAN FRANCISCO, Calif., May 19, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (OTC: CALA) (the “Company”) announced that it intends to hold a special meeting of stockholders on or about June 29, 2023 (the “Special Meeting”), fo…
The Peninsula company's plan to close by the end of the first quarter is atypical in a biotech industry where executives try to keep their companies alive to the next milestone in order to raise more money. Continue reading
Calithera Biosciences Inc (NASDAQ: CALA) announced that its Board of Directors has determined that it is in the best interests of its shareholders to dissolve the company and liquidate its assets. To reduce costs and in connection with the…
SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of potential strategic alternatives, that…
Calithera Biosciences, Inc. SOUTH SAN FRANCISCO, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), today announced that its Board of Directors has determined, after extensive consideration of potential s…
Calithera Biosciences, Inc. -- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, November 14, 2022 -- SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-sta…
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the third quarter ended Se…
Calithera Biosciences, Inc. SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company’s third quarter…
SOUTH SAN FRANCISCO, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company’s third quarter 2022 financial results will…
KalVista Pharmaceuticals, Inc. KALV faced a major setback when it decided to terminate the phase II KOMPLETE study evaluating its investigational oral plasma kallikrein inhibitor, KVD824, for the prophylactic treatment of hereditary angioe…
Shares of Calithera Biosciences Inc. jumped 14.6% in premarket trading on Monday after the company said it received a Fast Track designation for its experimental treatment for non-small cell lung cancer. The drug is currently being tested…
Calithera Biosciences, Inc. Enrollment ongoing in Phase 2 study evaluating sapanisertib, a dual mTORC1/2 inhibitor, in patients with squamous non-small cell lung cancer harboring a NRF2 mutation SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (…
SOUTH SAN FRANCISCO, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that the U.S. Food & Drug Administration (FDA) has g…
Shares of Spectrum Pharmaceuticals, Inc. SPPI were down 32.6% on Friday after the company announced that the FDA's Oncologic Drugs Advisory Committee (“ODAC”) did not vote in favor of its pipeline candidate, poziotinib, for the treatment o…
Pacira BioSciences, Inc. PCRX announced positive top-line data from a phase III study evaluating its marketed drug, Exparel, as a single-dose sciatic nerve block in the popliteal fossa for postsurgical regional analgesia in patients underg…
The question of when to add risk to a portfolio is a difficult one to answer. A rush toward riskier equities after the pandemic-induced sell-off led to a surge in many stocks. Among the biggest winners were penny stocks whose relatively lo…
Calithera Biosciences, Inc. SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, P…
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the company’s founder,…
HC Wainwright updated its model on Calithera Biosciences Inc (NASDAQ: CALA), reflecting the recent Q2 earnings with no revenues and a net loss of $1.69 per share for 2022. The analyst upgraded the rating to Buy from Neutral with a price ta…
Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and mining exploration companies often lose money for years before finding success with a new treatment or mineral discovery.…
Joining me today are Susan Molineaux, founder, president, and CEO; and Emil Kuriakose, chief medical officer. Before we begin, I would like to remind you that today's discussion will include statements about our future expectations, plans,…
SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced its financial results for the second quarter ended J…
Calithera Biosciences, Inc. -- Conference Call and Webcast Scheduled for 5:00 p.m. ET on Monday, August 15, 2022 -- SOUTH SAN FRANCISCO, Calif., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage…
Calithera Biosciences, Inc. SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company’s second quarter…
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision-oncology biopharmaceutical company, today announced Company’s second quarter 2022 financial results will…
We’ve seen a spate of stock splits in 2022, including from high-profile companies, such as Amazon (NASDAQ:AMZN) and Alphabet (NASDAQ:GOOG, NASDAQ:GOOGL). But while a stock split may too familiar for you, a reverse split is not a very commo…
Calithera Biosciences, Inc. -- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- -- First data from phase 1 investigator-sponsored clinical st…
-- Overview of phase 2 study evaluating SYK inhibitor mivavotinib in patients with relapsed/refractory non-GCB (ABC) diffuse large B-cell lymphoma -- -- First data from phase 1 investigator-sponsored clinical study of TORC 1/2 inhibitor sa…
Calithera Biosciences, Inc. -- Patients with tumors harboring NRF2-mutations have a poorer prognosis and no available targeted therapies -- SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq:…
-- Patients with tumors harboring NRF2-mutations have a poorer prognosis and no available targeted therapies -- SOUTH SAN FRANCISCO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, pr…
We just saw a spate of stock-spit announcements, including from high-profile companies, such as Amazon (NASDAQ:AMZN). While a stock split may be all too familiar for you, a reverse split is not a very common corporate action. In this artic…
Calithera Biosciences, Inc. -- Novel biomarker will be used to identify patients in genetically defined subgroup associated with poorer outcomes -- Study will evaluate SYK inhibitor both in patients with wild-type disease and those with tu…